Different ways to order SYLVANT® (siltuximab)

SYLVANT
100 MG
NDC: ‍73090-420-01a		 SYLVANT
400 MG
NDC: ‍73090-421-01a
Authorized
Dealer		 Phone
Number		 Website Item # Item #
ASD Healthcare 800-746-6273 10253123 10253031
Cardinal Health Specialty Distribution 877-453-3972 5694179 5694187
McKesson Plasma and Biologics 877-625-2566 1592724 1592773
McKesson Specialty Care Distribution 800-482-6700 5010694 5010695
Oncology Supply 800-633-7555 10253087 10253059

aSYLVANT® National Drug Code Updated as of 2/19/21.

R.A.R.E.SM can help

R.A.R.E. (Recordati Access, Resources, and Engagement) is designed to make it easier for your patients to access and stay on treatment.

R.A.R.E. support may include

  • Patient Adherence Support
  • Navigating the Insurance Process
  • Co-pay Program
  • Patient Assistance Program
Contact the R.A.R.E. Patient Support Program Monday-Friday, 9 AM to 6 PM ET: 1-855-299-8844
Two iMCD patients stand back to back to represent the support of Patient Connect. Not actual patients

Personalized support for your patients while on SYLVANT therapy

The Patient Liaison (PL) is ready to connect on SYLVANT® (siltuximab) and idiopathic multicentric Castleman disease (iMCD) with your patients who opt in

Helga, Patient Liaison Helga, Patient Liaison

The PL Program* offers people receiving SYLVANT therapy access to one‑on‑one support at no additional cost by Recordati Rare Diseases.

*PL services are provided by Recordati Rare Diseases to help support patients while on SYLVANT therapy. Information provided by the PL Program is for educational purposes only and is not intended to replace the advice of the healthcare provider. This is an opt-in program, which requires enrollment before PL services can be provided.

The Patient Liaison will call enrolled patients to:

1

Provide education and answer questions about iMCD and SYLVANT

2

Help patients access SYLVANT medication

3

Connect patients with other iMCD educational resources†

†PL Program services are available in Spanish.

To get started, your patients can complete the Program Enrollment Opt‑In Form

COMPLETE THE OPT-IN FORM

The PL will contact your patients upon receipt of the opt-in form.

The PL can help connect your patients with a variety of resources:

Access and reimbursement
support

  • Insurance verification—Confirming that your patients’ insurance companies will cover SYLVANT and help with understanding their insurance benefits
  • Insurance company education—Educating insurers about SYLVANT to help speed up decisions about coverage and payment

Financial assistance

  • Co-pay assistance program—Direct your patients to learn about co-pay eligibility for SYLVANT infusions in an outpatient care setting
  • Patient Assistance Program (PAP)—Help your patients access SYLVANT if they are eligible and do not have insurance or if they are underinsured
  • Additional referrals—Refer your patients to outside assistance sources if appropriate

Castleman Disease Collaborative
Network (CDCN)

The CDCN is a global initiative dedicated to accelerating research and treatment for Castleman disease.

logo

Additional Tools

Dosing and Administration Guide

Learn more about the administration process, including preadministration laboratory testing here.

Doctor Discussion Guide

See what patients who research iMCD may use when talking to their doctors about iMCD.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

SYLVANT is guideline-preferred for all patients with iMCD, regardless of severity.

CDCN Diagnostic Criteria

Though the road to diagnosing iMCD can be challenging, diagnostic criteria are available to help make the process easier.

Abbreviations: CDCN, Castleman Disease Collaborative Network; NCCN, National Comprehensive Cancer Network.

See More

SYLVANT® (siltuximab) for injection

INDICATIONS AND USAGE

SYLVANT® (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Limitations of Use
SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.

SYLVANT® (siltuximab) for injection

INDICATIONS AND USAGE

SYLVANT® (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Limitations of Use
SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.

IMPORTANT SAFETY INFORMATION

SYLVANT is contraindicated in patients experiencing a severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.

Concurrent Active Severe Infections: Do not administer SYLVANT to patients with severe infections until the infection resolves. SYLVANT may mask signs and symptoms of acute inflammation including suppression of fever and of acute Phase reactants such as C-reactive protein (CRP). Monitor patients receiving SYLVANT closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT until the infection resolves.

Vaccinations: Do not administer live vaccines to patients receiving SYLVANT because IL-6 inhibition may interfere with the normal immune response to new antigens.

Infusion Related Reactions and Hypersensitivity: Stop the infusion of SYLVANT if the patient develops signs of anaphylaxis. Discontinue further therapy with SYLVANT.

Stop the infusion if the patient develops a mild to moderate infusion reaction. If the reaction resolves, the SYLVANT infusion may be restarted at a lower infusion rate. Consider medicating with antihistamines, acetaminophen, and corticosteroids. Discontinue SYLVANT if the patient does not tolerate the infusion following these interventions.

Administer SYLVANT in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.

Gastrointestinal (GI) Perforation: Gastrointestinal (GI) perforation has been reported in clinical trials although not in MCD trials. Use with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with symptoms that may be associated or suggestive of GI perforation.

The most common adverse reactions (>10% compared to placebo) in the MCD clinical trial were rash, pruritus, upper respiratory tract infections, increased weight, and hyperuricemia.

Cytochrome P450 Substrates: Upon initiation or discontinuation of SYLVANT, in patients being treated with CYP450 substrates with a narrow therapeutic index, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) as needed and adjust dose. The effect of SYLVANT on CYP450 enzyme activity can persist for several weeks after stopping therapy. Exercise caution when SYLVANT is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).

Pregnancy and Lactation: SYLVANT may cause embryo-fetal harm when administered to pregnant women. Advise female patients of reproductive potential to use effective contraception during treatment with SYLVANT and for 3 months after the last dose. Advise females not to breastfeed during treatment with SYLVANT and for 3 months after the final dose.

Dosing and Administration: Perform hematology laboratory tests prior to each dose of SYLVANT therapy for the first 12 months and every 3 dosing cycles thereafter. If treatment criteria outlined in the Prescribing Information are not met, consider delaying treatment with SYLVANT. Do not reduce dose.

Before prescribing SYLVANT, please read the full Prescribing Information.